First AD

Second AD

Patient-Reported Outcomes and Quality of Life Data With T-DXd in HER2-(Ultra) Low mBC

Video content above is prompted by the following:

What insights do the patient-reported outcomes and quality of life data from the 

 trial show, and how might these findings inform patient care?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Recent Advances in the Treatment of Advanced   HER2+ Breast Cancer: SABCS 2024 

Peer Exchange

Panelists discuss how trastuzumab deruxtecan (T-DXd) demonstrated favorable patient-reported outcomes and quality of life measures in HER2-low  hormone receptor-positive metastatic breast cancer patients in DESTINY-Breast06, suggesting it could be a well-tolerated therapeutic option that maintains patients' daily functioning while providing clinical benefit.